Annual report
8473.TEDINET S100OSES
Period2021-04-01 → 2022-03-31
Filed2022-07-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amended by S100YKCS (2026-06-25).
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥763.6bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue2 IFRS |
| Revenue | ¥541.1bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue2 IFRS |
| Revenue | ¥368.1bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥351.4bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥337.0bn | 2017-04-01 → 2018-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Profit before tax | ¥412.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥140.4bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥65.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥83.0bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥71.8bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥366.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥81.1bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥37.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥52.5bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥46.7bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥355.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥97.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥17.84T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥7.21T | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥5.51T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.03T | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥4.54T | at 2018-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥16.25T | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥6.49T | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.58T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥717.1bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥593.7bn | at 2020-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥924.6bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥562.1bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥451.5bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥456.7bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥427.8bn | at 2018-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥2.50T | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥802.7bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥843.8bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥714.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥437.1bn | at 2018-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥314.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥178.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥26.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥71.7bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥33.2bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥1.84T | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥82.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥70.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥54.7bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥7.9bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥163.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥210.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥181.6bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥407.7bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥74.6bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥1,498.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥339.78 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥163.18 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥231.43 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥220.54 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥1,285.9 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥296.92 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥147.44 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥205.42 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥196.88 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥3,770.84 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,297.87 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,955.91 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,000.82 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,937.72 | at 2018-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 5.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 7.8% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 8.2% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 9.1% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 9.4% | at 2018-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 49.4% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.0% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.9% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.6% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 17,496 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 9,209 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 8,003 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 6,439 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 5,391 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥77.1bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥88.9bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥31.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥30.4bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥50.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥70.8bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥44.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥69.6bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥9.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.5bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥41.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥22.5bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥36.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥23.5bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥10.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.5bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.28T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.09T | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥894.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥780.5bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥758.2bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥891.5bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥693.5bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥387.2bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥392.5bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥351.1bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥358.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥377.4bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥74.5bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥50.9bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥149.89 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.46 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.61 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.03 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.77 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥127.18 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥84.11 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥41.28 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.27 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥41.2 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥150 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥120 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥85 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,571.37 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,598.81 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,515.98 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,565.37 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,707.02 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 30.1% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.8% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.7% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.5% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 245,220,890 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,639,390 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 236,556,393 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 236,556,393 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 224,561,761 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 203 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 212 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 227 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 224 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 197 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 8
| Segment | Item | Period | Value |
|---|---|---|---|
| Biotechnology Healthcare And Medical Informatics Businessgeography candidate | employees | at 2022-03-31 | 133 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 179 pure |
| Asset Management Businessreportable segment | employees | at 2022-03-31 | 2817 pure |
| Financial Services Businessreportable segment | employees | at 2022-03-31 | 14211 pure |
| —segment total | employees | at 2022-03-31 | 17161 pure |
| Asset Management Businessreportable segment | employees | at 2022-03-31 | 15 pure |
| Financial Services Businessreportable segment | employees | at 2022-03-31 | 32 pure |
| —segment total | employees | at 2022-03-31 | 47 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,671
| Item | Context | Value | Unit |
|---|---|---|---|
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration | 9458000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 393822000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 317581000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | 9218000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration_ReportableSegmentsMember | 720621000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 43370000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration_ReconcilingItemsMember | -373000000 | JPY |
| Revenue from external customers2 IFRS | CurrentYearDuration | 763618000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 2357000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 250000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | 702000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration_ReportableSegmentsMember | 3309000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 923000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration_ReconcilingItemsMember | -4232000000 | JPY |
| Intersegment revenue2 IFRS | CurrentYearDuration | － | JPY |
| Revenue2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 396179000000 | JPY |
| Revenue2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 317831000000 | JPY |
| Revenue2 IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | 9920000000 | JPY |
| Revenue2 IFRS | CurrentYearDuration_ReportableSegmentsMember | 723930000000 | JPY |
| Revenue2 IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 44293000000 | JPY |
| Revenue2 IFRS | CurrentYearDuration_ReconcilingItemsMember | -4605000000 | JPY |
| Revenue2 IFRS | CurrentYearDuration | 763618000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 282924000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 165962000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | -11845000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration_ReportableSegmentsMember | 437041000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -11990000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration_ReconcilingItemsMember | -12327000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 412724000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 86571000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 122893000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | -37000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration_ReportableSegmentsMember | 209427000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 254000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration_ReconcilingItemsMember | -262000000 | JPY |
| Interest income segment IFRS | CurrentYearDuration | 209419000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 10806000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 26426000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | 695000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration_ReportableSegmentsMember | 37927000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 790000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration_ReconcilingItemsMember | 3441000000 | JPY |
| Interest expense segment IFRS | CurrentYearDuration | 42158000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000FinancialServicesBusinessReportableSegmentMember | 20826000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000AssetManagementBusinessReportableSegmentMember | 3940000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E05159-000BiotechnologyHealthcareAndMedicalInformaticsBusinessMember | 416000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_ReportableSegmentsMember | 25182000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5692000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_ReconcilingItemsMember | 1239000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |